Despite initial anti-tumor activity observed in recent clinical trials, CAR T cell therapy has failed to reproducibly provide a prolonged clinical benefit, mainly attributed to T cell functional exhaustion, typically characterized by high levels of PD1 and other immunosuppressive markers. This evidence concerns the gene PDCD1 and neoplasm.